Development

Excipients for High-Concentration Biologics

Careful selection is essential for achieving viscosity reduction without protein destabilization.

The Rise of Regenerative Medicines

Regenerative medicines boast a rich clinical pipeline.

What’s Next for COVID-19 Vaccines and Variants?

New technologies and treatments are emerging—along with new variants.

FDA Launches Accelerated Rare Disease Cures Program

May 11, 2022

The agency’s Center for Drug Evaluation and Research has launched the new program to increase development of treatment options for patients with rare diseases.

Shining a Spotlight on Nucleic Acid-Based Therapeutics

May 11, 2022

Further development of nucleic acid-based therapeutics has been accelerated by the recent success of mRNA vaccines.

AstraZeneca Announces Plans for New Strategic R&D Center

May 05, 2022

AstraZeneca has announced plans to open a new strategic R&D center in Cambridge, MA, which will also serve as Alexion’s headquarters.

Driving Efficiencies in DSP Separation and Purification

May 03, 2022

An increasingly complex development pipeline and industry considerations, such as sustainability, are leading to a greater need for more efficient separation and purification in downstream processing.

Emerging Therapies Face Development Hurdles

May 02, 2022

Complex hurdles complicate the development of emerging therapies.

Emerging Plant-based Platform for Biomanufacturing

May 02, 2022

Plant-based manufacturing technology gains mainstream edge in biopharmaceutical production.

An Evolving Approach to Drug Delivery

May 02, 2022

Advances in therapeutic modalities and an increase in molecular complexity have led to the need for an evolution in drug delivery approaches over the years.

Johnson & Johnson Launches Next Satellite Center for Global Health Discovery

April 26, 2022

Johnson & Johnson has launched its next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town.

EIB Provides €15 million to IRBM

April 21, 2022

The European Investment Bank has provided €15 million to fund coronavirus research at IRBM.

Otsuka Pharmaceutical and Osaka University Enter Exclusive License Agreement

April 20, 2022

Otsuka Pharmaceutical and Osaka University have entered an exclusive license agreement on a new anti-tumor antibody.